The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with ...

Nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or ...

A federal vaccine advisory committee plans to review the childhood vaccination schedule and scrutinize vaccines that have ...

At the start of today’s meeting, ACIP's new chair, Martin Kulldorff, PhD, a statistician and epidemiologist formerly at ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy preterm and full-term infants, putting MSD in a position to potentially file ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, ...

On Wednesday, the eight new members of the CDC’s Advisory Committee on Immunization Practices will begin a 2-day meeting in ...

A reshaped agenda for the Centers for Disease Control and Prevention’s vaccine advisory committee meeting on June 25–26 ...

Sen. Cassidy voices concerns over new ACIP members' lack of expertise in microbiology and mRNA vaccines after the ousting of ...